

Advances in Endometrial Ablation Techniques for Heavy Menstrual Bleeding

Tamer A. Addissouky ^{1,2,3} *, Ibrahim El Tantawy El Sayed ², Majeed M. A. Ali ¹, Yuliang Wang ⁴, and Ahmed A. Khalil ⁵

¹ Al-Hadi University College, Baghdad, Iraq.

² Department of Biochemistry, Science Faculty, Menoufia University, Menoufia, Egypt.

³ MLS ministry of health, Alexandria, Egypt. - MLS ASCP, USA.

⁴ Joint International Research Laboratory of Metabolic and Developmental Sciences, Key Laboratory of Urban Agriculture (South) Ministry of Agriculture, Plant Biotechnology Research Center, Fudan-SJTU-Nottingham Plant Biotechnology R&D Center, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.

⁵ Department of Pathology, BayState Medical Center, Springfield, Massachusetts, UNITED STATES.

***Corresponding Author:** Tamer A. Addissouky, Al-HADI University College, Baghdad, Iraq. - Department of Biochemistry, Science Faculty, Menoufia University, Egypt. - MLS ministry of health, Alexandria, Egypt. - MLS, ASCP, USA.

Received date: January 05, 2024; **Accepted date:** January 19, 2024; **Published date:** January 25, 2024

Citation: Tamer A. Addissouky., Ibrahim El Tantawy El Sayed., Majeed M. A. Ali., Yuliang Wang., and Ahmed A. Khalil. (2024), Advances in Endometrial Ablation Techniques for Heavy Menstrual Bleeding, *J. Women Health Care and Issues*. 7(1); DOI:10.31579/2642-9756/183

Copyright: © 2024, Tamer A. Addissouky. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Endometrial ablation is an established uterus-sparing treatment for heavy menstrual bleeding (HMB), but average amenorrhea rates remain around 50%. Ablation limitations and side effects have spurred interest in less invasive alternatives.

Purpose: This review comprehensively surveys emerging endometrial ablation techniques, regenerative and pharmaceutical options, and future directions in HMB management. It provides an updated synthesis of the latest promise and pitfalls in both established and novel therapeutic approaches.

Main body: Global ablation methods have reduced operative risks versus first generation hysteroscopic options, but treatment failures still occur. Innovations like magnetic resonance-guided focused ultrasound ablation, endometrial resection, and temporary hormonal suppression aim to further expand choices, improve outcomes, and avoid permanent ablation. However, comparative effectiveness studies are lacking and optimal patient selection unclear. This review highlights promising areas of research, while delineating limitations and knowledge gaps needing further study.

Conclusion: Continued innovation and investigation of less invasive options may personalize therapy and reduce ablation complications and retreatment rates. But robust evidence on long-term fertility, regeneration, quality of life, and cost-effectiveness is still needed guide best practices in this evolving field.

Key words: endometrial ablation; heavy menstrual bleeding; pharmaceutical options; endometrial resection

1. Introduction

Heavy menstrual bleeding (HMB), defined as excessive menstrual blood loss of over 80mL per cycle, is a common gynecological disorder estimated to affect up to 30% of women worldwide. The excessive blood loss and duration of menstruation associated with HMB can have a significant detrimental impact on a woman's physical, social, emotional and material quality of life. Anemia resulting from chronic iron deficiency is a common complication. As women age, the prevalence of HMB tends to increase due to conditions like adenomyosis, fibroids and coagulation disorders [1]. When medical management of HMB fails, endometrial ablation has emerged as an

effective alternative to hysterectomy. Endometrial ablation is a procedure that destroys the lining of the uterus (endometrium) in order to reduce or stop excessive menstrual bleeding. First generation ablation techniques utilized hysteroscopically-guided destruction of the endometrium by heated fluid, laser or electrosurgery. Global ablation methods were later introduced, which destroy the entire endometrium at once using thermal balloon, radiofrequency electrical energy, cryotherapy or microwave energy without visual guidance [2].

While clinical trials have shown endometrial ablation provides significant improvement in HMB and quality of life in most women, limitations exist. Average amenorrhea (cessation of periods) rates are only around 50% and treatment failure or unsatisfactory improvement in bleeding occurs in 15-30% of women. Post-ablation pain, infection, uterine perforation, asherman's syndrome and other complications can also occur. For these reasons, research is ongoing to evaluate new technologies and refine ablation techniques [3]. While endometrial ablation fills an important niche in heavy menstrual bleeding treatment, limitations like suboptimal amenorrhea rates, pain, and treatment failure affecting up to 30% of women underscore the need for continued innovation. This review provides an updated synthesis of emerging ablation techniques, regenerative approaches, and pharmaceutical alternatives. It delineates latest developments, knowledge gaps, and future directions in this evolving field [4]. While endometrial ablation is an established treatment for heavy menstrual bleeding, average amenorrhea rates remain only around 50% and complications prompt re-treatment in 15-30% of women. This underscores the need to survey emerging technologies like focused ultrasound, novel resection devices, and temporary pharmaceutical options that may expand choices, limit side effects, and improve outcomes. By comprehensively evaluating the latest evidence on both conventional and innovative approaches, this review provides updated recommendations to guide optimal integration of traditional techniques with disruptive innovations in this rapidly evolving ablation field.

II. Current endometrial ablation techniques

Feature	First Generation (Hysteroscopic)	Second Generation (Global)
Methods	Heated fluid, laser, electrosurgery	Thermal balloon, radiofrequency, cryoablation, microwave
Visualization	Requires hysteroscope	Blind, no hysteroscope
Skill required	High surgical skill	Less operator dependent
OR time	Longer	Shorter
Anesthesia	General anesthesia	Local anesthesia or none
Risks	Higher perforation risk	Thermal injury, treatment failure

Table 1. Comparison of First and Second Generation Endometrial Ablation Techniques

III. Innovations and alternatives to endometrial ablation

While global endometrial ablation techniques have evolved considerably, there is continued interest in developing less invasive approaches with improved outcomes. One promising noninvasive innovation is magnetic resonance-guided focused ultrasound ablation (MRgFUS).

III.1. Magnetic resonance-guided focused ultrasound

Magnetic resonance-guided focused ultrasound (MRgFUS) allows for precise ablation of the endometrial lining using high-intensity focused ultrasound energy guided by MR thermal imaging. The ultrasound waves penetrate through the abdomen to heat and coagulate the endometrium, without need for incisions [11]. Early feasibility studies of MRgFUS ablation in women with HMB have demonstrated significant reduction in menstrual bleeding at 6-12 months [12]. Potential advantages of MRgFUS include its noninvasive nature, lack of anesthesia requirement, and real-time monitoring abilities. MR thermal mapping allows selective targeting of ablation while imaging confirms the uterus remains intact [13]. However, MRgFUS requires costly specialized equipment and highly trained personnel. Treatment sessions are lengthy and not all uterine morphology allows

adequate sonication. Larger studies with longer follow-up are still needed [14]. Alternatives to endometrial destruction are also being explored, including conservative resection of the endometrium while sparing the deeper myometrium. This may promote regeneration of a normal uterine lining after surgery. Temporary medical hormonal suppression of the endometrium with oral contraceptives, progestins or GnRH agonists is another option, but may require long-term treatment [15].

First generation endometrial ablation techniques utilized direct visualization of the uterine cavity with a hysteroscope to guide destruction of the endometrium [5]. Heated fluid, laser energy or electrosurgery with a rollerball could be directed to the lining. These hysteroscopic methods required additional training, surgical skill and longer operating room time [6]. Global endometrial ablation was later introduced as a second generation approach, allowing the entire endometrium to be treated at once without visually guiding the ablation. Common global ablation modalities include heated liquid-filled balloons, radiofrequency electrical energy, cryoablation probes and microwave devices inserted transcervically into the uterus [7].

Each ablation modality has unique benefits and risks. Heated fluid techniques like the thermal balloon can treat variable uterine shapes and are less dependent on operator skill [8]. Radiofrequency ablation is fast, simple and does not require general anesthesia in the outpatient setting. Cryoablation and microwave energy have the advantages of myocardial ablation devices which selectively destroy the endometrium while sparing deeper myometrium [9]. In clinical studies, global endometrial ablation has equaled or exceeded the amenorrhea rates of hysteroscopic ablation, ranging from 45-75% after 1 year. Global ablation is also associated with shorter operating room time, quicker recovery, less pain and reduced risk of uterine perforation. However, complications like infection, hematometra, thermal injury or treatment failure may still occur. Retreatment with ablation, hysterectomy or alternative therapies is required in 15-30% of women within 5 years due to unsatisfactory bleeding control [10].

Endometrial resection is a newer technique that aims to remove rather than destroy the endometrial lining. During resection, a shaving device is inserted into the uterus transcervically. This allows accurate removal of the endometrium down to the superficial myometrium while sparing the deeper uterine muscle layers [16]. Early pilot studies of endometrial resection have shown promise in reducing HMB with less risk of adhesions compared to ablation. One randomized trial found resection resulted in lighter bleeding and higher satisfaction rates versus rollerball ablation at 1 year follow-up. The preservation of deeper myometrium may enable regeneration of normal endometrial tissue over time [17]. **Figure 1,**

III.2. Endometrial resection

Endometrial resection is a newer technique that aims to remove rather than destroy the endometrial lining. During resection, a shaving device is inserted into the uterus transcervically. This allows accurate removal of the endometrium down to the superficial myometrium while sparing the deeper uterine muscle layers [16]. Early pilot studies of endometrial resection have shown promise in reducing HMB with less risk of adhesions compared to ablation. One randomized trial found resection resulted in lighter bleeding and higher satisfaction rates versus rollerball ablation at 1 year follow-up. The preservation of deeper myometrium may enable regeneration of normal endometrial tissue over time [17]. **Figure 1,**




Figure 1. Proposed Origins of Endometrial Stem Cells [18]

outlines two hypothesized endogenous sources of human endometrial stem cells that contribute to endometrial regeneration and repair. One theory proposes stromal-type stem cells located around endometrial glands and vessels. These stromal stem cells expressing markers like CD90, CD146, and LGR5 reside in both the functional and basal layers. An alternative theory suggests epithelial-like stem cells situated near the gland bases and blood

vessels within the basal layer. These epithelial progenitor cells express genes like DNMT3B, OCT-4, and SSEA-1. While the specific origins remain unclear, evidence indicates the endometrium harbors both stromal and epithelial stem cell niches. Further characterization of distinctive stem cell populations and their regenerative mechanisms will advance understanding of endometrial physiology [18]. **Figure 2,**




Figure 2. Characteristics of Endometrial Stem Cells [18]

outlines key features of endometrial stem cells that have been identified based on biomarkers associated with stem cell functions. Research has focused on genes involved in self-renewal, pluripotency, and differentiation potential in other stem cell types to characterize endometrial stem cells. Markers of self-renewal capacity include BIRC5, CCND1, MYC, and TERT, which regulate cell proliferation and survival. Pluripotency markers comprise NANOG, OCT4, SOX2, and KLF4, which maintain an

undifferentiated state. Lineage differentiation markers include PAX2, HOXA10, WT1 (stromal/mesenchymal lineage), CK18 and E-cadherin

(epithelial lineage). Other putative markers are Telomerase, Musashi-1, SSEA-1, NOTCH1, CD44, CD146, and CD140b [18].

Potential advantages of endometrial resection include avoiding permanent destruction of the uterine lining. This could reduce risks like asherman's syndrome. The precise, tissue-sparing approach may lead to more normal menstruation long-term in some women. However, more data is needed on long-term regeneration and comparison to ablation outcomes. Endometrial resection remains an investigational approach requiring further study.

Technology	Mechanism	Potential Benefits	Status
MR-guided Focused Ultrasound	High intensity focused ultrasound	Noninvasive, no anesthesia, precise	Early feasibility studies
Plasma ablation	Ionized gas	Improved ablation precision	Clinical trials ongoing
Hydrothermal ablation	Heated saline	Conforms to uterine shape	Awaits FDA approval

Table 2. Innovative Endometrial Ablation Technologies in Development

III.3. Pharmaceutical options

Rather than destroying or removing the uterine lining, pharmaceutical therapies aim to thin the endometrium to reduce menstrual blood flow. The levonorgestrel intrauterine device (IUD) releases a progestin to inhibit endometrial proliferation. Oral contraceptives containing estrogen and progestins work similarly [19]. Gonadotropin-releasing hormone (GnRH) agonists induce a hypoestrogenic state by suppressing ovarian function, leading to endometrial atrophy. These drug therapies reduce HMB by 40-60% on average by creating a thin, inactive endometrium [20].

The advantages of pharmaceutical treatment include avoiding surgery and preserving fertility and the uterine anatomy. However, limitations exist. Some women have contraindications to hormonal therapy. Drug effects may be incomplete or temporary if therapy is discontinued. Long-term treatment may be required, which has implications for adherence and cost [21]. For these reasons, medication is often considered first-line for HMB, while endometrial ablation is reserved for women who fail or decline drug therapy. More comparative data is needed to delineate their roles in HMB treatment algorithms.

Drug Class	Examples	Mechanism	Limitations
Hormonal IUD	Levonorgestrel IUD	Local progestin effect	Need replacement every 3-5 years
Combined oral contraceptives	Estrogen/progestin pills	Suppresses endometrial proliferation	Daily adherence, side effects
GnRH agonists	Leuprolide, goserelin	Pituitary downregulation, hypogonadism	Temporary effect, side effects

Table 3. Medical Therapy Options for Heavy Menstrual Bleeding

IV. Herbal remedies and traditional medicine for heavy menstrual bleeding

Alongside pharmaceutical options, some women seek out complementary and alternative medicine approaches for heavy menstrual bleeding, including herbal preparations and traditional practices [22]. Several natural supplements have shown promise in reducing HMB symptoms [23]. Chasteberry (*Vitex agnus-castus*) can inhibit FSH and prolactin, reducing estrogen effects on the endometrium. Studies show chasteberry extracts may decrease menstrual blood loss by over 50% in women with HMB [24]. Turmeric (*Curcuma longa*) and its active ingredient curcumin also have antifibrinolytic and anti-inflammatory properties that can stabilize clots and potentially decrease menstrual flow [25].

Traditional Chinese medicine utilizes acupuncture and herbal formulations like dang gui, mu dan pi, and chi shao to treat “flooding and leaking” imbalances implicating the liver, spleen and kidneys. A meta-analysis found acupuncture significantly reduced HMB blood loss versus controls. However, quality evidence is still limited on specific traditional remedies. Safety concerns also exist regarding herb-drug interactions and contaminants in unregulated preparations [26]. Some women seek complementary medicine options when pharmaceutical treatments fail or are contraindicated. These natural approaches may impart benefit, but likely have a more ancillary role given the limited comparative effectiveness data. Additional research is warranted on standardized herbal extracts and acupuncture protocols to clarify their utility as safer adjuncts to conventional therapy. Open communication between patients and clinicians about complementary

medicine use is advised to avoid potential interactions with standard HMB treatments [27-31].

V. Nanomedicine applications

The emerging field of nanomedicine seeks to apply engineered nanomaterials for therapeutic delivery and diagnostic advances [32]. Some nanotechnology applications show early promise for improving endometrial ablation techniques and HMB medical management. For instance, iron oxide nanoparticles have been proposed as a method to enable noninvasive ablation using alternating magnetic fields applied externally to heat and coagulate tissue. This concept of nanoheaters has been demonstrated in animal models but not yet studied for endometrial targets [33]. Nanoparticle-mediated drug delivery is another area of active research. Liposomes, dendrimers, carbon nanotubes and polymeric nanoparticles can allow sustained uterine release of contraceptives or antifibrinolytic agents to regulate menstrual bleeding with less systemic exposure. Early studies using nanoparticle carriers for levonorgestrel demonstrate extended uterine retention and endometrial atrophy in animal models [34]. However, substantial research is still required to translate these nanomedicine concepts into safe and effective HMB therapies. Challenges include optimizing nanocarrier design for uterine targeting, understanding nanoparticle

biodistribution and toxicity, and progressing through phased clinical trials [35]. If development continues, nanotechnology may someday provide novel ablation modalities or enable advanced drug delivery systems for personalized, non-permanent HMB treatment [36].

VI. Artificial intelligence role in endometrial ablation and HMB treatment

Artificial intelligence (AI) and machine learning have potential to transform medical decision-making and treatment through data-driven insights [37]. In endometrial ablation, AI-assisted models could help guide patient selection and predict individualized outcomes using clinical, imaging, and genomic data. Intelligent algorithms may also optimize ablation parameters for each patient scenario [38]. During procedures, AI-enabled robotic systems could draw on population data to provide real-time guidance on optimal device positioning and energy delivery [39]. This could standardize techniques and minimize user-dependent variability. Post-operatively, machine learning with longitudinal data may better forecast ablation success versus risk of complication or retreatment need. However, robust datasets from diverse patient populations are required to develop and validate reliable AI models [40]. Limitations exist regarding real-world applicability and generalizability. Thoughtful integration of AI-tools with clinical judgement will be critical, as will probing model recommendations to avoid inequities. With further accrual of high-quality data and progress in responsible AI practices, machine learning offers enormous potential to personalize ablation treatments and improve HMB outcomes. But clinical translation remains in early stages [41].

VII. Personalized Medicine Approaches

Precision endometrial ablation relies on identifying prognostic factors to select optimal treatments for each woman. Imaging like saline-infused sonography can evaluate cavity deformities, while newer modalities like virtual hysteroscopy offer enhanced pre-procedural planning [42]. Uterine biomarkers and genomic classifiers are also under exploration to predict ablation response. Patient-reported outcome scales assessing quality of life, menstrual history, and bleeding impact can also inform treatment decisions [43]. Ongoing research seeks to develop integrated prognostic models incorporating clinical data like age, dysmenorrhea, bleeding patterns, and failed medications [44]. Customized pre-treatment assessments may guide choice of ablation method, energy dose, duration, and ancillary techniques to improve outcomes. However, robust evidence is still needed before pretreatment profiles can reliably determine best options for targeted HMB therapy [45].

VIII. Lifestyle Modifications

Along with medical treatment, evidence supports the integration of certain lifestyle changes to help ameliorate heavy menstrual bleeding. Regular aerobic exercise has been shown to reduce HMB duration and blood loss by improving uterine vasculature and inhibiting prostaglandins [46]. Stress management via yoga, meditation, or cognitive behavioral therapy can decrease HMB severity by mitigating cortisol effects on menstrual cycles. Dietary modifications may also help - increased fiber, soy isoflavones, omega-3s, and vitamin supplements have demonstrated benefit in small studies [47]. Lifestyle optimization offers a low-risk adjunct to medical therapy, empowering women to self-manage HMB impact. However, quality data on specific regimens is limited. A personalized approach is recommended, assessing nutrition, activity, sleep, and stress reduction needs. Holistic wellness promotion should be a routine part of HMB management [48].

IX. Future directions

Further development and rigorous evaluation of emerging non-invasive ablation techniques like MR-guided focused ultrasound ablation is a critical area needing additional research. While early feasibility studies show promise, longer-term comparative effectiveness trials are still required to fully assess if these novel approaches can improve amenorrhea rates and reduce complications versus existing global endometrial ablation methods [49]. Optimization of newer endometrial resection devices and techniques is another active area, seeking to enable precise, tissue-sparing removal of the endometrial lining while avoiding permanent destruction. This concept of a reversible ablation aims to promote regeneration of normal endometrium long-term. However, robust comparative data on long-term outcomes like fertility, recurrence risk, and patient satisfaction is still lacking compared to standard ablation [50]. Investigation of temporary pharmaceutical suppression of endometrial proliferation and menstruation using oral contraceptives, levonorgestrel IUDs, and GnRH agonists represents a third major research direction [51]. These medical alternatives to permanent ablation warrant further study regarding their roles and sequencing in HMB treatment algorithms. Critical knowledge gaps remain regarding optimal duration of drug therapy, comparative efficacy and quality of life impacts, and identification of ideal candidates [52]. Advancing the fledgling field of nanomedicine for HMB treatment is another active frontier, seeking to enable novel ablation modalities and advanced uterotrophic drug delivery systems [53]. But substantial translational research is still needed to demonstrate the safety and effectiveness of concepts like iron oxide nanoheater ablation and nanoparticle-mediated hormone carriers [54].

X. Conclusions

Endometrial ablation has evolved into an effective uterus-sparing therapy for heavy menstrual bleeding, with global techniques reducing risks and limitations of earlier hysteroscopic options. However, average amenorrhea rates remain only around 50% and complications like pain, infection, and repeat procedures still affect 15-30% of women. This underscores the need for continued research and innovation to expand choices, limit side effects, and improve outcomes. MR-guided focused ultrasound ablation represents one particularly promising novel modality in early feasibility testing, offering a completely noninvasive approach utilizing thermal imaging guidance. While advantages are apparent, comparative data is still lacking. Endometrial resection is another emerging technique using a tissue-sparing shaving approach aimed at enabling regeneration. However, robust evidence on long-term impacts is needed. Temporary pharmaceutical therapies like oral contraceptives, the levonorgestrel IUD, and GnRH agonists also warrant further study to clarify their optimal sequencing with ablation. In summary, while great progress has been made in endometrial ablation techniques, important limitations persist. Ongoing innovation and investigation of less invasive options holds promise for more personalized therapy with reduced complications. But rigorous comparative effectiveness data, long-term follow-up, and clarification of optimal patient selection criteria are still required to guide best practices in this continually evolving field.

XI. Recommendations

- Larger controlled trials directly comparing novel approaches like MR-guided focused ultrasound ablation and endometrial resection to current global ablation methods are strongly recommended to elucidate comparative risks, benefits, and long-term outcomes.
- Research should seek to identify clinical, imaging, genetic, and patient-reported factors associated with optimal ablation outcomes in order to develop prognostic models enabling personalized procedure selection and customization.

- Studies are needed on the fertility and pregnancy outcomes following different ablation techniques, both after regeneration and without intervening therapy. This would better delineate reversibility potential.
- Cost-effectiveness analyses should evaluate emerging ablation modalities compared to standard approaches, incorporating impacts on retreatment, complications, quality of life, and healthcare utilization.
- Additional high-quality randomized trials are warranted comparing temporary pharmaceutical therapies to ablation for guiding evidence-based HMB treatment algorithms and optimal sequencing.
- Lifestyle modification studies should assess tailored regimens integrating diet, exercise, stress reduction, and wellness promotion as adjuncts to medical management of heavy menstrual bleeding.

Abbreviations:

HMB - Heavy menstrual bleeding

MRgFUS - Magnetic resonance-guided focused ultrasound ablation

OR - Operating room

GnRH - Gonadotropin-releasing hormone

IUD - Intrauterine device

FDA - Food and Drug Administration

Declarations:

Ethics approval and consent to participate: Not Applicable

Consent for publication: Not Applicable

Availability of data and materials: all data are available and sharing is available as well as publication.

Competing interests: The authors hereby that they have no competing interests.

Funding: Corresponding author supplied all study materials. There was no further funding for this study.

Authors' contributions: The authors completed the study protocol and were the primary organizers of data collection and the manuscript's draft and revision process. Tamer A. Addissouky wrote the article and ensured its accuracy. All authors contributed to the discussion, assisted in designing the study and protocol and engaged in critical discussions of the draft manuscript. Lastly, the authors reviewed and confirmed the final version of the manuscript.

Acknowledgements: The authors thank all the researchers, editors, reviewers, and the supported universities that have done great efforts on their studies. Moreover, we are grateful to the editors, reviewers, and reader of this journal.

References

1. Ibrahim PM, Samwel EL. (2023). Prevalence of Heavy Menstrual Bleeding and Its Associated Factors Among Women Attending Kilimanjaro Christian Medical Centre In Northern Eastern, Tanzania: A Cross-Sectional Study. *East Afr Health Res J*.7(1):1-6.
2. Vitale SG, Della Corte L, Ciebiera M, Carugno J, Riemma G, Lasmar RB, Lasmar BP, Kahramanoglu I, Urman B, Mikuš M, De Angelis C, Török P, Angioni S. Hysteroscopic Endometrial Ablation: From Indications to Instrumentation and Techniques-A Call to Action. *Diagnostics (Basel)*. 2023 Jan 17;13(3):339.
3. Reinders IMA, van de Kar MRD, Geomini PMAJ, Leemans JC, Maas JWM, Bongers MY. Short-term recovery after NovaSure® endometrial ablation: a prospective cohort study. *Facts Views Vis Obgyn*. 2022 Dec;14(4):299-307.
4. Kakinuma T, Kaneko A, Kakinuma K, Matsuda Y, Yanagida K, Takeshima N, Ohwada M. Effectiveness of treating menorrhagia using microwave endometrial ablation at a frequency of 2.45 GHz. *World J Clin Cases* 2023; 11(24): 5653-5659.
5. Smith, P.P., Clark, T.J. (2023). Operative Hysteroscopy. In: Shoupe, D. (eds) *Handbook of Gynecology*. Springer, Cham.
6. MacGregor, Becky, Malcolm G. Munro, and Mary A. Lumsden. "Therapeutic Options for the Management of Abnormal Uterine Bleeding." *International Journal of Gynecology & Obstetrics* 162, 43-57. Accessed January 4, 2024.
7. Heylen, Anna, Jasper Verguts, Lieselore Vandermeulen, and Thierry Van den Bosch. "Pregnancy following Ablation Therapy: A Literature Review." *Journal of Endometriosis and Uterine Disorders* 4, (2023): 100046. Accessed January 4, 2024.
8. Hussain S, Sohrabi C, Providencia R, Ahsan S, Papageorgiou N. Catheter Ablation for the Management of Atrial Fibrillation: An Update of the Literature. *Life (Basel)*. 2023 Aug 21;13(8):1784.
9. Koshiro Kanaoka, Taku Nishida, Yoshitaka Iwanaga, Michikazu Nakai, Reina Tonegawa-Kuji, Yuichi Nishioka, Tomoya Myojin, Katsuki Okada, Tatsuya Noda, Kengo Kusano, Yoshihiro Miyamoto, Yoshihiko Saito, Tomoaki Imamura, Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks, *European Heart Journal*, 2023;., ehad798,
10. Minami, Yasunori, Tomoko Aoki, Satoru Hagiwara, and Masatoshi Kudo. 2023. "Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma" *Cancers* 15, no. 19: 4763.
11. Lerner VT, Donnellan NM, Siedhoff MT, Truong MD, King CR. Care Delivery for Patients with Leiomyomas: Failures, Real-Life Experiences, Analysis of Barriers, and Proposed Restorative Remedies. *Health Equity*. 2023 Aug 25;7(1):439-452.
12. Jiang, Y.; Qin, S.; Wang, Y.; Liu, Y.; Liu, N.; Tang, L.; Fang, J.; Jia, Q.; Huang, X. Intravoxel Incoherent Motion Diffusion-Weighted MRI for Predicting the Efficacy of High-Intensity Focused Ultrasound Ablation for Uterine Fibroids. *Frontiers in Oncology* 2023, 13.

13. Labate, Angelo, Salvatore Bertino, Rosa Morabito, Chiara Smorto, Annalisa Militi, Simona Cammaroto, Carmelo Anfuso, Francesco Tomaiuolo, Paolo Tonin, Silvia Marino, and et al. 2023. "MR-Guided Focused Ultrasound for Refractory Epilepsy: Where Are We Now?" *Journal of Clinical Medicine* 12, no. 22: 7070.
14. Shu C, Lim M, Fang A. Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors. *Life (Basel)*. 2023 Jun 30;13(7):1485.
15. Kweon S, Park J, Sim Y, Kwack JY, Kwon YS. Clinical Outcomes of Conservative Surgery for Diffuse Uterine Leiomyomatosis: Preliminary Experience of 17 Cases in a Single Center. *J Clin Med*. 2023 Dec 12;12(24):7638.
16. Catena U, Mirandola M, Capomacchia FM, Fanfani F, Scambia G. A new surgical approach for fertility-sparing management of diffuse endometrial G2 endometrioid adenocarcinoma: a step-by-step technique. *Facts Views Vis Obgyn*. 2023 Mar;15(1):79-81.
17. Yan, J., Wu, T., Zhang, J. et al. Revolutionizing the female reproductive system research using microfluidic chip platform. *J Nanobiotechnol* 21, 490 (2023).
18. Hong IS. Endometrial stem/progenitor cells: Properties, origins, and functions. *Genes Dis*. 2022 Aug 31;10(3):931-947.
19. Heting M, Wenping L, Yanan W, Dongni Z, Xiaoqing W, Zhli Z. Levonorgestrel intrauterine system and breast cancer risk: An updated systematic review and meta-analysis of observational studies. *Heliyon*. 2023 Mar 22;9(4):e14733.
20. Surrey ES. GnRH agonists in the treatment of symptomatic endometriosis: a review. *F S Rep*. 2022 Nov 21;4(2 Suppl):40-45.
21. Gupta, Divya, Shubham Singh, Sangeeta Shukla, and Sadhana Shrivastava. "Oncofertility: Treatment Options from Bench to Bedside." *Cancer Pathogenesis and Therapy* 1, no. 4 (2023): 284-289. Accessed January 4, 2024.
22. Es-Hagheeh Ashtean S, Vahid Dastjerdi M, Tabarrai M, Nejatbakhsh F, Sadati Lamardi SN, Rahmani A, Azizkhani M, Tavoli Z. Effectiveness of Persian Golnar on Excessive Menstrual Bleeding in Women with Abnormal Uterine Bleeding, Compared to Tranexamic Acid: A Triple-Blind, Randomized Equivalence Trial. *Evid Based Complement Alternat Med*. 2023 Jul 20;2023:5355993.
23. Puglia LT, Lowry J, Tamagno G. Vitex agnus castus effects on hyperprolactinaemia. *Front Endocrinol (Lausanne)*. 2023 Nov 21;14:1269781.
24. Addissouky TA, et al. efficiency of mixture of olive oil and figs as an antiviral agents: a review and perspective, *International Journal of Medical Science and Health Research*, ISSN:2581-3366, Volume 4, Issue 4, Aug 2020, page 107-111,
25. Chen, Huize, Chujun Deng, Zeyu Meng, and Shengxi Meng. "Effects of TCM on Polycystic Ovary Syndrome and Its Cellular Endocrine Mechanism." *Frontiers in Endocrinology* 14, (2023): 956772. Accessed January 4, 2024.
26. Amzajjerdi, A., Keshavarz, M., Ghorbali, E. et al. The effect of vitamin D on the severity of dysmenorrhea and menstrual blood loss: a randomized clinical trial. *BMC Women's Health* 23, 138 (2023).
27. T A Addissouky, A A Khalil, A E El Agroudy, Assessment of potential biomarkers for early detection and management of Glomerulonephritis patients with diabetic diseases, *American Journal of Clinical Pathology*, Volume 160, Issue Supplement_1, November 2023, Pages S18–S19,
28. T A Addissouky, A A Khalil, A E El Agroudy, Assessing the Efficacy of a Modified Triple Drug Regimen Supplemented with Mastic Gum in the Eradication of Helicobacter pylori Infection, *American Journal of Clinical Pathology*, Volume 160, Issue Supplement_1, November 2023, Page S19,
29. T A Addissouky, A A Khalil, Detecting Lung Cancer Stages Earlier By Appropriate Markers Rather Than Biopsy And Other Techniques, *American Journal of Clinical Pathology*, Volume 154, Issue Supplement_1, October 2020, Pages S146–S147,
30. Tamer Addissouky, Detecting Liver Fibrosis by Recent Reliable Biomarkers in Viral Hepatitis Patients, *American Journal of Clinical Pathology*, Volume 152, Issue Supplement_1, October 2019, Page S85.
31. Addissouky, T.A., Sayed, I.E.T.E., Ali, M.M.A. et al. Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. *Egypt Liver Journal* 14, 2 (2024).
32. Sahni, Maneesha, and Emily S. Day. "Nanotechnologies for the Detection and Treatment of Endometriosis." *Frontiers in Biomaterials Science* 2, (2023): 1279358. Accessed January 4, 2024.
33. Yuxue J, Ran S, Minghui F, Minjia S. Applications of nanomaterials in endometriosis treatment. *Front Bioeng Biotechnol*. 2023 May 9;11:1184155.
34. Addissouky, T.A., Wang, Y., El Sayed, I.E. et al. Recent trends in Helicobacter pylori management: harnessing the power of AI and other advanced approaches. *Beni-Suef Univ J Basic Appl Sci* 12, 80 (2023).
35. Haque, Munima, Md Salman Shakil, and Kazi Mustafa Mahmud. 2023. "The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment" *Cancers* 15, no. 6: 1892.
36. von Ende E, Ryan S, Crain MA, Makary MS. Artificial Intelligence, Augmented Reality, and Virtual Reality Advances and Applications in Interventional Radiology. *Diagnostics (Basel)*. 2023 Feb 27;13(5):892.
37. Chen M, Kong W, Li B, Tian Z, Yin C, Zhang M, Pan H, Bai W. Revolutionizing hysteroscopy outcomes: AI-powered uterine myoma diagnosis algorithm shortens operation time and reduces blood loss. *Front Oncol*. 2023 Dec 8;13:1325179.
38. Addissouky TA, El Tantawy El Sayed I, Ali MMA, Wang Y, El Baz A, Khalil AA, et al. Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions *J Cell Immunol*. 2023;5(4):127-126.
39. Zhao A, Du X, Yuan S, Shen W, Zhu X, Wang W. Automated Detection of Endometrial Polyps from Hysteroscopic Videos Using Deep Learning. *Diagnostics (Basel)*. 2023 Apr 13;13(8):1409.
40. E, K., S, P., R, G. et al. Advantages and pitfalls in utilizing artificial intelligence for crafting medical examinations: a medical education pilot study with GPT-4. *BMC Med Educ* 23, 772 (2023).
41. Giudice LC, Oskotsky TT, Falako S, Opoku-Anane J, Sirota M. Endometriosis in the era of precision medicine and impact on sexual and reproductive health across the lifespan and in diverse populations. *FASEB J*. 2023 Sep;37(9):e23130.
42. Yang J, Barkley JE, Bhattarai B, Firouzi K, Monk BJ, Coonrod DV, Zenhausem F. Identification of Endometrial Cancer-Specific microRNA Biomarkers in Endometrial Fluid. *Int J Mol Sci*. 2023 May 12;24(10):8683.
43. Addissouky TA, Ali MMA, El Tantawy El Sayed I, Wang Y, El Baz A, Elarabany N, et al. Preclinical Promise and Clinical Challenges for Innovative Therapies Targeting Liver Fibrogenesis. *Arch Gastroenterol Res*. 2023;4(1):14-23.
44. Liu, Yujiang, Wanwan Wen, Linxue Qian, and Ruifang Xu. "Safety and Efficacy of Microwave Ablation for Abdominal Wall Endometriosis: A Retrospective Study." *Frontiers in Surgery* 10, (2023): 1100381. Accessed January 4, 2024.
45. Siminiuc R, Turcanu D. Impact of nutritional diet therapy on premenstrual syndrome. *Front Nutr*. 2023 Feb 1;10:1079417.

46. Addissouky T, Ali M, El Tantawy El Sayed I, Wang Y. Revolutionary Innovations in Diabetes Research: From Biomarkers to Genomic Medicine. *IJDO* 2023; 15 (4) :228-242
 47. Vafaei, Somayeh, Michał Ciebiera, Mervat M. Omran, Mohammad Mousaei Ghasroldasht, Qiwei Yang, Tanya Leake, Rochelle Wolfe, Mohamed Ali, and Ayman Al-Hendy. 2023. "Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach)" *International Journal of Molecular Sciences* 24, no. 21: 15972.
 48. Patel N, Chaudhari K, Patel D, Joshi J. High-Intensity Focused Ultrasound Ablation of Uterine Fibroids: A Review. *Cureus*. 2023 Sep 4;15(9):e44680.
 49. Candiani M, Ottolina J, Salmeri N, D'Alessandro S, Tandoi I, Bartiromo L, Schimberni M, Ferrari S, Villanacci R. Minimally invasive surgery for ovarian endometriosis as a mean of improving fertility: Cystectomy vs. CO2 fiber laser ablation what do we know so far? *Front Surg*. 2023 Mar 27;10:1147877.
 50. Whitaker LHR, Middleton LJ, Daniels JP, et al. Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding (UCON): a randomised controlled phase III trial. *EClinicalMedicine*. 2023 May 18;60:101995.
 51. MacGregor, Becky, Malcolm G. Munro, and Mary A. Lumsden. "Therapeutic Options for the Management of Abnormal Uterine Bleeding." *International Journal of Gynecology & Obstetrics* 162, 43-57. August 2023.
 52. Swingle, K.L., Ricciardi, A.S., Peranteau, W.H. et al. Delivery technologies for women's health applications. *Nat Rev Bioeng* 1, 408–425 (2023).
- Chehelgerdi, M., Chehelgerdi, M., Allela, O.Q.B. et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. *Mol Cancer* 22, 169 (2023).



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

Submit Manuscript

DOI: [10.31579/2642-9756/183](https://doi.org/10.31579/2642-9756/183)

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://www.auctoresonline.org/journals/women-health-care-and-issues>